Effect of a polymorphonuclear elastase inhibitor (Sivelestat sodium) on acute lung injury after cardiopulmonary bypass: Findings of a double-blind randomized study

Masahiro Ryugo, Yoshiki Sawa, Hiroshi Takano, Goro Matsumiya, Shigemitsu Iwai, Masamichi Ono, Hiroki Hata, Takashi Yamauchi, Masaji Nishimura, Yuji Fujino, Hikaru Matsuda

Research output: Contribution to journalArticlepeer-review

37 Scopus citations

Abstract

Purpose. We evaluated the effect of sivelestat sodium (SiV), a novel synthesized polymorphonuclear (PMN) elastase inhibitor, on acute lung injury (ALI) caused by cardiopulmonary bypass (CPB). Methods. Fourteen patients who underwent cardiopulmonary surgery using CPB, followed by the development of both systemic inflammatory response syndrome (SIRS) and ALI, were treated with either 0.2 mg/kg per hour SiV (SiV group, n = 7) or saline (control group, n = 7) for 4 days from the time of arrival in the intensive care unit. Results. The SiV group had a significantly lower ratio of serum PMN elastase and interleukin (IL)-8, a significantly lower ratio of the respiratory index, and a significantly higher ratio of PaO2/FiO2 after 24 h of treatment than the control group. Conclusion. Sivelestat sodium suppressed the production of PMN elastase and IL-8, resulting in improved respiratory function in patients with ALI caused by CPB.

Original languageEnglish
Pages (from-to)321-326
Number of pages6
JournalSurgery Today
Volume36
Issue number4
DOIs
StatePublished - Apr 2006
Externally publishedYes

Keywords

  • Acute lung injury
  • Cardiopulmonary bypass
  • Polymorphonuclear elastase
  • Postperfusion syndrome
  • Sivelestat sodium
  • Systemic inflammatory response syndrome

Fingerprint

Dive into the research topics of 'Effect of a polymorphonuclear elastase inhibitor (Sivelestat sodium) on acute lung injury after cardiopulmonary bypass: Findings of a double-blind randomized study'. Together they form a unique fingerprint.

Cite this